MitaMed Ltd.
Interventional endoscopy and electroporation
This article was originally published in Start Up
Executive Summary
MitaMed Ltd.’s EndoVE allows for minimally invasive, non-thermal tumor ablation via the end of a standard endoscope. In conjunction with the delivery of a small dose of a chemotherapeutic, the device is placed at the tumor site, then delivers a series of eight, low-energy, electrical pulses directly to the tumor cells, increasing their porosity and thus boosting the absorption rate of the chemotherapy drug.
You may also be interested in...
OncoSec Medical Inc.
OncoSec Medical Inc. has developed electroporation-based technology for deadly Stage III and IV metastatic melanoma, and two rare but aggressive orphan skin cancer indications. Its ImmunoPulse platform delivers DNA IL-12 into electroporated cells, triggering each cell to produce and secrete the IL-12 protein, which in turn identifies and eliminates cancerous cells as part of a natural immune response.
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.